Alan J. Tuchman - 30 Jun 2025 Form 4 Insider Report for TAO Synergies Inc. (SNPX)

Reporting relationship: Chief Medical Officer, Director
Issuer ticker: SNPX
Reported as of: 30 Jun 2025
Net transaction value: -$13,549
SEC form: 4
Accepted by SEC: 02 Jul 2025, 16:05:04 UTC
Prior SEC filing: 20 Dec 2022
Next SEC filing: 05 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Robert Weinstein, Attorney-in-fact

Key filing fact

Alan J. Tuchman filed Form 4 for TAO Synergies Inc. (SNPX) on 02 Jul 2025.

Key facts

This page summarizes Alan J. Tuchman's Form 4 filing for TAO Synergies Inc. (SNPX).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 02 Jul 2025, 16:05.

Change

Previous filing in this sequence was filed on 20 Dec 2022.
Current net transaction value: -$13,549.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001417631 Primary reporting owner

TUCHMAN ALAN J

Relationship: Chief Medical Officer, Director
Address: C/O TAO SYNERGIES INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK
Signature: /s/ Robert Weinstein, Attorney-in-fact
Signature date: 02 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TAOX transaction

Common Stock, par value $0.0001 per share

Award

Transaction value: $0
Shares: +4,315
Change %: +327%
Price: $0.000000
Shares after: 5,635
Date: 30 Jun 2025
Ownership: Direct
Footnotes: F1

TAOX transaction

Common Stock, par value $0.0001 per share

Tax liability

Transaction value: $13,549
Shares: -1,726
Change %: -31%
Price: $7.85
Shares after: 3,909
Date: 30 Jun 2025
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Includes (i) 4,315 restricted stock units granted on June 30, 2025, under the Issuer's 2020 Equity Incentive Plan which vested immediately upon issuance and (ii) 1,320 shares of common stock.

Footnote F2

Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction.